You wouldn't in most cases. The diagnosis of multiple myeloma is usually made based upon the clinical presentation, serum or urine protein studies and morphology and does not require flow cytometry. Flow cytometry may be useful in diagnostic evaluation of patients with hematologic abnormalities who have increased plasma cells of unknown nature in the marrow but no definite clonal immunoglobulin in serum or urine and no characteristic clinical or radiological findings of myeloma. It can also be used to determine the proliferative index- which is of prognostic value. Maryalice Stetler-Stevenson, M.D., Ph.D. Chief, Flow Cytometry Unit Laboratory of Pathology, NCI, NIH Sometimes you're the windshield, sometimes you're the bug. > ---------- > From: Ierachmiel Daskal > Sent: Tuesday, March 26, 2002 8:54 AM > To: Cytometry Mailing List > Subject: Re: Missing Myeloma cells > > > In an era of cost containment and limited resources, why would you do a > flow analysis > of a bone aspirate to diagnose myeloma? > > Ierachmiel Daskal M.D. PhD. FCAP, FASCP > Chairman > Department of Pathology and Laboratory Medicine > (215) 456-6126 > Pager: 2-3559 > daskali@einstein.edu > > >>> "Melvin Hasseler" <hasseler@hsc.usc.edu> 03/22/02 01:47PM >>> > It has been our experience that when we add CD45 PerCP as a third color to > our > cytoplasmic Kappa/138 & Lambda/138 tubes on bone marrow samples suspected > of having > myeloma cells, the cells seem to have variable amounts of CD45 or slam > against the left > with zero CD45 PerCP staining. In our two color analyzes myeloma cells are > negative > to dim for CD45. Our compensation appears to be correct for the other > markers, bright > or dim, when we add CD45 PerCP. > > Mel Hasseler > Supervisor, USC Flow Cytometry Section In Los Angeles > >
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:26:05 EST